Please assess the completion status of the following clinical trial:

Trial Title: Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ages 7-70 years old~* Renal biopsy, diagnostic for IgA nephropathy~* Must be able to take oral medication~Exclusion Criteria:~* Clinical and histologic evidence of systemic lupus erythematosus~* Well-documented history of Henoch-Schonlein purpura.~* Clinical evidence of cirrhosis or chronic liver disease~* Abnormal laboratory values at the time of study entry~* Estimated GFR outside of protocol defined limits~* History of significant gastrointestinal disorder~* Active systemic infection or history of serious infection within one month of entry or known infection with HIV, hepatitis B, or hepatitis C.~* Other major organ system disease or malignancy~* Current or prior treatment with MMF or azathioprine

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Mycophenolate Mofetil (MMF) (Type: ACTIVE_COMPARATOR): Dose is based on body size (between 25mg/kg/day and 36mg/kg/day with a maximum dose 1gm BID; initial dose to be used in the first 2 weeks of therapy will be approximately 1/2-2/3 of the full dose). Route of administration is oral. Frequency is daily. MMF will be administered up to 12 months.
- MMF Placebo (Type: PLACEBO_COMPARATOR): Subjects receive MMF placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).